Minireviews
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Aug 9, 2018; 8(4): 97-101
Published online Aug 9, 2018. doi: 10.5500/wjt.v8.i4.97
Review of stem cells as promising therapy for perianal disease in inflammatory bowel disease
Francis E Dailey, Erica P Turse, Maliha Naseer, Jack D Bragg, Veysel Tahan
Francis E Dailey, Erica P Turse, Maliha Naseer, Jack D Bragg, Veysel Tahan, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri Health Center, Columbia, MO 65212, United States
Francis E Dailey, Erica P Turse, Maliha Naseer, Jack D Bragg, Veysel Tahan, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri-Columbia, Columbia, MO 65212, United States
Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: No potential conflicts of interest. No financial support.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Veysel Tahan, FACG, FACP, FESBGH, MD, Assistant Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri Health Center, One Hospital Drive, CD 405, Columbia, MO 65212, United States. tahanv@health.missouri.edu
Telephone: +1-573-8846044 Fax: +1-573-8844595
Received: March 29, 2018
Peer-review started: March 29, 2018
First decision: April 10, 2018
Revised: April 22, 2018
Accepted: June 8, 2018
Article in press: June 9, 2018
Published online: August 9, 2018
Processing time: 133 Days and 18.7 Hours
Abstract

Those patients with perianal Crohn’s disease or ulcerative colitis experience a difficult to treat disease process with a delayed state and often inability to heal despite current therapies. The approaches currently used to treat these patients with corticosteroids, antibiotics, immunomodulators, anti-tumor necrosis factor-α drug, and surgical repair are limited in their healing ability. This review presents all current literature since emergence in the early 2000s of stem cell therapy for patients with perianal inflammatory bowel disease and analyzes the efficacy, outcomes and safety within these studies.

Keywords: Crohn’s disease, Stem cells, Mesenchymal, Perianal disease, Fistula, Inflammatory bowel disease

Core tip: Allogeneic and autologous mesenchymal stem cells (MSCs) are being researched for use in patients with refractory perianal Crohn’s disease. Studies from 2003 until now demonstrate efficacy and safety of MSC therapy in this patient population. Up until now, there are no large multi-center, randomized double-blind, placebo-controlled studies examining this.